Total Payments
$293,846
2024 Payments
$65,955
Companies
20
Transactions
315
Medicare Patients
1,336
Medicare Billing
$411,406
Payment Breakdown by Category
Other$190,702 (64.9%)
Consulting$69,413 (23.6%)
Travel$27,347 (9.3%)
Food & Beverage$6,071 (2.1%)
Education$313.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $183,156 | 60 | 62.3% |
| Consulting Fee | $69,413 | 21 | 23.6% |
| Travel and Lodging | $27,347 | 112 | 9.3% |
| Honoraria | $7,546 | 2 | 2.6% |
| Food and Beverage | $6,071 | 113 | 2.1% |
| Education | $313.64 | 7 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $150,061 | 166 | $0 (2024) |
| GlaxoSmithKline, LLC. | $44,683 | 34 | $0 (2024) |
| PharmaEssentia USA Corporation | $28,749 | 26 | $0 (2024) |
| Celgene Corporation | $28,638 | 35 | $0 (2022) |
| SOBI, INC | $14,518 | 7 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $9,871 | 3 | $0 (2023) |
| Blueprint Medicines Corporation | $8,696 | 9 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $2,478 | 3 | $0 (2021) |
| ABBVIE INC. | $2,256 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,988 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,955 | 48 | Incyte Corporation ($23,416) |
| 2023 | $62,231 | 58 | Incyte Corporation ($20,829) |
| 2022 | $54,287 | 67 | Incyte Corporation ($25,030) |
| 2021 | $28,059 | 34 | Incyte Corporation ($15,376) |
| 2020 | $30,884 | 25 | Incyte Corporation ($23,837) |
| 2019 | $40,787 | 49 | Incyte Corporation ($30,238) |
| 2018 | $5,738 | 16 | Incyte Corporation ($5,596) |
| 2017 | $5,906 | 18 | Incyte Corporation ($5,739) |
All Payment Transactions
315 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,110.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/03/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,740.00 | General |
| Category: Hematology/Oncology | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $114.11 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $42.21 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $31.49 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/30/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | Incyte Corporation | NIKTIMVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 09/17/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,082.50 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $93.95 | General |
| 08/16/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $4,162.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/14/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Consulting Fee | Cash or cash equivalent | $4,998.00 | General |
| Category: Oncology | ||||||
| 07/31/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | Cash or cash equivalent | $22.78 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Inari Medical, Inc. | FLOWTRIEVER CATHETER, S (Device), CT THROMBECTOMY SYSTEM KIT | Food and Beverage | In-kind items and services | $189.14 | General |
| Category: VTE | ||||||
| 07/01/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,740.00 | General |
| Category: Hematology/Oncology | ||||||
| 06/26/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,027.50 | General |
| Category: Hematology/Oncology | ||||||
| 06/24/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $128.26 | General |
| Category: Hematology/Oncology | ||||||
| 06/24/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Hematology/Oncology | ||||||
| 06/24/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $17.39 | General |
| Category: Hematology/Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 291 | 933 | $378,866 | $103,621 |
| 2022 | 10 | 368 | 1,010 | $303,557 | $96,187 |
| 2021 | 8 | 356 | 1,033 | $304,566 | $97,392 |
| 2020 | 10 | 321 | 1,243 | $399,941 | $114,206 |
Total Patients
1,336
Total Services
4,219
Medicare Billing
$411,406
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 100 | 397 | $150,860 | $47,330 | 31.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 277 | $120,265 | $27,631 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 116 | $53,426 | $15,054 | 28.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 31 | $19,618 | $4,507 | 23.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 20 | 20 | $11,140 | $2,988 | 26.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 41 | $11,836 | $2,720 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 36 | $9,216 | $2,614 | 28.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 15 | $2,505 | $775.18 | 30.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 69 | 257 | $97,660 | $31,671 | 32.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 57 | 338 | $91,598 | $29,368 | 32.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 81 | 201 | $51,456 | $16,113 | 31.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 26 | 37 | $22,036 | $6,039 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 49 | 68 | $11,356 | $3,772 | 33.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $10,026 | $2,832 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 23 | $7,295 | $2,581 | 35.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 14 | 15 | $3,840 | $1,174 | 30.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 19 | $3,667 | $1,147 | 31.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 14 | 19 | $3,173 | $1,079 | 34.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 13 | 15 | $1,450 | $411.77 | 28.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 68 | 245 | $93,100 | $29,916 | 32.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 42 | 300 | $81,300 | $26,763 | 32.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 104 | 275 | $70,400 | $22,408 | 31.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 74 | 124 | $20,708 | $6,925 | 33.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 23 | 36 | $21,441 | $6,227 | 29.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $9,469 | $2,415 | 25.5% |
About Dr. Haris Ali, M.D
Dr. Haris Ali, M.D is a Internal Medicine healthcare provider based in Duarte, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1467672907.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Haris Ali, M.D has received a total of $293,846 in payments from pharmaceutical and medical device companies, with $65,955 received in 2024. These payments were reported across 315 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($183,156).
As a Medicare-enrolled provider, Ali has provided services to 1,336 Medicare beneficiaries, totaling 4,219 services with total Medicare billing of $411,406. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hematology
- Location Duarte, CA
- Active Since 04/26/2007
- Last Updated 03/07/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1467672907
Products in Payments
- JAKAFI (Drug) $132,982
- OJJAARA (Drug) $34,073
- BESREMI (Drug) $28,749
- INREBIC (Drug) $16,089
- VONJO (Drug) $14,496
- Inrebic (Drug) $10,421
- XPOVIO (Drug) $9,871
- AYVAKIT (Drug) $8,696
- PEMAZYRE (Drug) $1,845
- NIKTIMVO (Drug) $685.00
- FLOWTRIEVER CATHETER, S (Device) $189.14
- CALQUENCE (Drug) $164.96
- Ultomiris (Drug) $128.03
- Pomalyst (Drug) $115.85
- Imbruvica (Drug) $99.00
- ADCETRIS (Biological) $98.42
- DARZALEX (Biological) $91.18
- IMBRUVICA (Drug) $52.32
- ULTOMIRIS (Biological) $42.39
- ONUREG (Drug) $24.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Duarte
Amrita Krishnan, Md, MD
Internal Medicine — Payments: $841,332
Internal Medicine $841,332
Dr. Daneng Li, M.d, M.D
Internal Medicine — Payments: $584,406
Internal Medicine $584,406
Alexey Danilov, M.d, M.D
Internal Medicine — Payments: $419,324
Internal Medicine $419,324
Marwan Fakih, Md, MD
Internal Medicine — Payments: $355,683
Internal Medicine $355,683
Dr. Tycel Phillips, M.d, M.D
Internal Medicine — Payments: $336,879
Internal Medicine $336,879
Dr. Tanya Siddiqi, M.d, M.D
Internal Medicine — Payments: $253,344
Internal Medicine $253,344